Filing summary
Entity mismatch: The request identifies Decoy Therapeutics Inc., but the supplied Form 10-Q is for Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX). The summary below describes the filing as provided, for the quarter ended June 30, 2022; financial statements are unaudited.
Business context and reporting period
Salarius is a clinical-stage biopharmaceutical company developing cancer treatments. Its pipeline included seclidemstat (SP-2577), in Phase 1/2 testing for relapsed or refractory Ewing sarcoma and in an investigator-initiated MDS/CMML trial, and SP-3164, acquired in January 2022 and in IND-enabling studies. The company had no approved products and no product-sale revenue.
Financial results and liquidity
| Metric | Three months ended June 30, 2022 | Six months ended June 30, 2022 |
|---|---|---|
| Revenue | $0 | $0 |
| Research and development expense | $2.92 million | $7.36 million |
| General and administrative expense | $1.84 million | $3.51 million |
| Net loss | $4.72 million | $10.83 million |
| Basic and diluted loss per share | $0.09 | $0.22 |
At June 30, 2022, cash and cash equivalents were $22.65 million, working capital was $20.2 million, total assets were $33.65 million, current liabilities were $2.77 million, and stockholders’ equity was $30.88 million. The balance sheet reports no long-term debt; the filing does not provide a separate debt-maturity or borrowing-capacity discussion. No meaningful operating margin is available because the company reported no revenue.
For the six months, operating cash use was $7.14 million, investing cash use was $1.50 million, and financing cash provided was $2.07 million. Cash decreased by $6.57 million from year-end 2021. The filing states that existing cash is not expected to fund operations through one year from the financial-statement issuance date and concludes that substantial doubt exists about the company’s ability to continue as a going concern.
Changes versus the prior comparable periods
- Second-quarter net loss increased by $1.64 million from $3.07 million in 2021; six-month net loss increased by $5.90 million from $4.93 million.
- Six-month R&D expense rose by $3.52 million, principally reflecting SP-3164 acquisition and development costs, alongside higher SP-2577 outsourced, personnel, and clinical-trial costs.
- Grant revenue fell to zero from $0.57 million for the quarter and $1.84 million for the six-month period in 2021. The company said eligible CPRIT funding had been exhausted, although it expected to receive a $1.6 million receivable.
- Six-month G&A expense rose by $0.59 million, attributed to higher personnel and public-company costs. Operating cash use increased by about $1.24 million year over year.
- Financing cash provided fell to $2.07 million from $27.86 million in the 2021 first half, when larger stock sales and warrant exercises generated proceeds.
Outlook, risks, and unusual items
- Management expects significant expenses and operating losses for at least the next several years and says additional capital will be needed. It may seek equity or debt financing, collaborations, or licensing/partnering arrangements, but gives no assurance of success or acceptable terms.
- The January SP-3164 transaction involved $1.5 million cash and 1 million shares valued at about $0.5 million, plus potential future milestone and royalty payments. The cash-flow statement records $1.99 million of in-process R&D expense and a $1.5 million investing outflow.
- In April, Salarius sold 9.34 million shares at $0.25 per share and warrants for up to 7.00 million additional shares at $0.3399. Gross proceeds were about $2.3 million; net financing proceeds were about $2.07 million. Shares outstanding rose to 56.12 million at June 30 from 45.24 million at year-end 2021.
- Nasdaq had extended the deadline to regain the $1.00 minimum bid-price requirement to November 14, 2022. Stockholders authorized a potential 1-for-5 to 1-for-30 reverse split; the board retained discretion over whether and how to implement it.
- The CPRIT agreement was extended through November 30, 2022. The company reported a $1.6 million receivable and disclosed that CPRIT could seek repayment of some or all disbursed grant funds if the agreement is terminated under specified circumstances.
- Management reported disclosure controls were effective at the reasonable-assurance level and no significant change in internal control during the quarter. The company reported no material legal proceedings and said COVID-19 had caused minimal disruption to date, while future effects remained uncertain.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Salarius Pharmaceuticals, Inc., not Decoy Therapeutics Inc.
- Assess the going-concern warning, cash burn, and timing and terms of any additional financing.
- Verify collection of the $1.6 million CPRIT receivable and the grant’s remaining obligations or repayment exposure.
- Track Nasdaq minimum-bid compliance and any reverse-split decision, as well as the dilution implications of outstanding warrants and future financing.
- Review SP-2577 trial progress and SP-3164 development milestones, costs, and any contingent acquisition payments.